-- Wedbush Securities週二在一份報告中指出，Passage Bio (PASG)面臨更艱難的處境。美國監管機構告知該公司，其實驗性療法PBFT02需要進行一項隨機對照試驗才能獲得批准，此舉增加了時間、成本和不確定性。 報告稱，儘管額顳葉失智症目前尚無核准療法，但PBFT02的隨機對照試驗將耗資龐大且耗時漫長。 Wedbush表示，正在進行的研究的生物標記結果仍然令人鼓舞，新的MRI數據也進一步支持該療法可能對患者有益。 Wedbush將Passage Bio的股票評級從“跑贏大盤”下調至“中性”，並將目標股價從32美元下調至8美元，原因是其估值中剔除了PBFT02。 Wedbush認為，該療法可能仍然具有潛力，但監管障礙過高，難以支撐更樂觀的看法。 報告顯示，Passage Bio 截至 2025 年底擁有 4,630 萬美元現金，Wedbush 的新目標價格反映了該公司在未來幾季實現兩位數營運支出削減後，預計到 2026 年底的每股現金。
Price: $6.01, Change: $-0.24, Percent Change: -3.84%
Sichuan Changhong Electric's (SHA:600839) attributable profit fell 72% to 98.5 million yuan in the first quarter from 345.5 million yuan in the year-ago period, according to a Saturday filing with the Shanghai bourse.Earnings per share at the consumer electronics manufacturer decreased 71% to 0.0214 yuan from 0.0748 yuan in the prior-year period.Operating income edged up 1.6% year over year to 27.3 billion yuan from 26.8 billion yuan.Shares decreased 5% during morning trading on Monday.
China Energy Engineering (SHA:601868, HKG:3996) logged a 29% year-on-year decrease in total new contract value in the first quarter of 2026, according to a Hong Kong bourse filing Friday.Hong Kong-listed shares of the construction firm fell over 2% in Monday late morning trade.The value of new contracts reached 276.2 billion yuan during the quarter, including 184.81 billion yuan from domestic sources and 91.39 billion yuan from overseas.
Shanghai Zhangjiang Hi-Tech Park Development's (SHA:600895) attributable profit fell 72% to 83.5 million yuan in the first quarter from 294.5 million yuan in the year-ago period, according to a Saturday filing with the Shanghai bourse.Earnings per share at the real estate developer decreased 72% to 0.05 yuan from 0.18 yuan in the prior-year period.Operating income declined 31% year over year to 838 million yuan from 1.22 biliion yuan.Shares decreased 3% during the midday trade on Monday.